Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates

Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates Abstract. The Transfusion Safety Study monitored susceptible persons for human immunodeficiency virus type 1 (HIV‐1) infections transmitted by plasma products and blood components. Through December, 1988, 6 subjects without antibody to HIV‐1 (anti‐HIV‐1) became seropositive after receiving dry‐heated factor VIII concentrate. The preparations implicated in 3 cases were derived entirely from anti‐HIV‐1‐screened donors. In all instances, HIV‐1 infection could be explained by concentrates heated at 60 °C for 24–30 h. Limiting consideration to concentrates and components administered after study entry showed that 4 of the seroconversions occurred among 122 subjects given 10 million units of factor VIII concentrates. No seroconversions occurred among 84 subjects given 5 million units of factor IX concentrates, or 83 who received components from over 26,000 unpaid donations. Serologic surveillance of anti‐HIV‐1‐negative subjects provides important information, and should be routine in the management of persons receiving clotting factor concentrates. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Vox Sanguinis Wiley

Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates

Loading next page...
 
/lp/wiley/transmission-of-human-immunodeficiency-virus-type-1-by-dry-heated-T3vozAa0M7

References (51)

Publisher
Wiley
Copyright
© 1990 S. Karger AG, Basel
ISSN
0042-9007
eISSN
1423-0410
DOI
10.1111/j.1423-0410.1990.tb00846.x
Publisher site
See Article on Publisher Site

Abstract

Abstract. The Transfusion Safety Study monitored susceptible persons for human immunodeficiency virus type 1 (HIV‐1) infections transmitted by plasma products and blood components. Through December, 1988, 6 subjects without antibody to HIV‐1 (anti‐HIV‐1) became seropositive after receiving dry‐heated factor VIII concentrate. The preparations implicated in 3 cases were derived entirely from anti‐HIV‐1‐screened donors. In all instances, HIV‐1 infection could be explained by concentrates heated at 60 °C for 24–30 h. Limiting consideration to concentrates and components administered after study entry showed that 4 of the seroconversions occurred among 122 subjects given 10 million units of factor VIII concentrates. No seroconversions occurred among 84 subjects given 5 million units of factor IX concentrates, or 83 who received components from over 26,000 unpaid donations. Serologic surveillance of anti‐HIV‐1‐negative subjects provides important information, and should be routine in the management of persons receiving clotting factor concentrates.

Journal

Vox SanguinisWiley

Published: Oct 1, 1990

There are no references for this article.